Login
Sign Up
Login
Sign Up
Features
Pricing
Reg.News
Contact
Login
Sign Up
Search
Providers
Companies
⨯
LIVE
Event in Progress:
Join Here
×
Search
Providers
Companies
⨯
Features
Pricing
Event Hub
Reg.News
Short Interest
Contact
All the news articles and press releases in one place.
UK Reg. News
German Reg. News
Search
Key Announcements
Results / Trading Updates
Get free RNS email alerts for@Model.CurrentFilterValue
Currently filtered for ReNeuron Group plc
Clear Filter
Sector
Automobile Industry
Banks
Basic Materials
Building & Construction
Chemicals
Consumer Discretionary Goods
Consumer Discretionary Services
Consumer Staple Goods
Consumer Staple Services
Discretionary Personal Goods
Discretionary Retail
Energy
ETFs
Finance
Financial Services
Food & Drink
Food Production
Health
Household Goods & DIY
Industrial
Industrial Equipment, Goods & Services
Insurance & Reinsurance
Investment Trusts
Leisure, Tourism & Travel
Media
Open-ended Funds
Other
Real Estate
Resources
Staple Retail
Technology
Telecoms
Trusts, ETFs & Funds
Utilities
Market Cap
Below £20m
£20m - £100m
£100m - £300m
£300m - £1bn
£1bn - £10bn
Over £10bn
Filters »
All
UK100
UK250
UK SmallCap
UK Other
Show:
10
25
50
100
«
1
2
3
»
Date / Time
Source
Ticker
Company
Sector
Market Cap
Announcement
16Jul18 07:00
RNS
AV:LON, RENE:LON
Aviva plc, ReNeuron Group plc
Various
Various
Notification of Major Holdings
13Jul18 11:50
RNS
AV:LON, RENE:LON
Aviva plc, ReNeuron Group plc
Various
Various
Notification of Major Holdings
12Jul18 07:00
RNS
RENE:LON
ReNeuron Group plc
Health
£1.74m
Preliminary Results
11Jul18 07:00
RNS
RENE:LON
ReNeuron Group plc
Health
£1.74m
Signs retinal stem cell exclusivity agreement
04Jul18 14:15
RNS
RENE:LON
ReNeuron Group plc
Health
£1.74m
Notification of Preliminary Results
17May18 07:00
RNS
RENE:LON
ReNeuron Group plc
Health
£1.74m
Capital Markets Event
04May18 07:00
RNS
RENE:LON
ReNeuron Group plc
Health
£1.74m
Exosome data presented at ISCT conference
30Apr18 07:00
RNS
RENE:LON
ReNeuron Group plc
Health
£1.74m
Capital Markets Event and Webcast
19Apr18 07:00
RNS
RENE:LON
ReNeuron Group plc
Health
£1.74m
Wins grant for retinal cell therapy development
10Apr18 13:00
RNS
RENE:LON
ReNeuron Group plc
Health
£1.74m
Appointment of US-based Chief Medical Officer
26Mar18 07:00
RNS
RENE:LON
ReNeuron Group plc
Health
£1.74m
Product Development Update
13Feb18 10:00
RNS
RENE:LON
ReNeuron Group plc
Health
£1.74m
Positive pre-clinical data in nerve injury
23Jan18 11:06
RNS
RENE:LON
ReNeuron Group plc
Health
£1.74m
Approval of Share Capital Reorganisation
11Jan18 07:00
RNS
RENE:LON
ReNeuron Group plc
Health
£1.74m
Further re Share Capital Reorganisation
05Jan18 07:00
RNS
RENE:LON
ReNeuron Group plc
Health
£1.74m
Proposed Share Capital Reorganisation
14Dec17 07:00
RNS
RENE:LON
ReNeuron Group plc
Health
£1.74m
Interim results
14Dec17 07:00
RNS
RENE:LON
ReNeuron Group plc
Health
£1.74m
Stroke clinical trial regulatory approval in US
08Dec17 07:00
RNS
RENE:LON
ReNeuron Group plc
Health
£1.74m
ReNeuron opens US office
13Nov17 11:30
RNS
RENE:LON
ReNeuron Group plc
Health
£1.74m
Notification of Interim Results
08Nov17 07:00
RNS
RENE:LON
ReNeuron Group plc
Health
£1.74m
Retinal disease clinical trial moves into Phase II
31Oct17 07:00
RNS
RENE:LON
ReNeuron Group plc
Health
£1.74m
Positive stroke clinical data & regulatory update
27Oct17 07:00
RNS
RENE:LON
ReNeuron Group plc
Health
£1.74m
Wins further UK grant
11Oct17 13:31
RNS
RENE:LON
ReNeuron Group plc
Health
£1.74m
PDMR Interest in Shares and Share Options
09Oct17 07:00
RNS
RENE:LON
ReNeuron Group plc
Health
£1.74m
Presentation of positive pre-clinical data
12Sep17 07:00
RNS
RENE:LON
ReNeuron Group plc
Health
£1.74m
Directors' Interest in Shares and Share Options
06Sep17 11:15
RNS
RENE:LON
ReNeuron Group plc
Health
£1.74m
Result of AGM
06Sep17 07:00
RNS
RENE:LON
ReNeuron Group plc
Health
£1.74m
AGM Trading Update
01Sep17 07:00
RNS
RENE:LON
ReNeuron Group plc
Health
£1.74m
Non-executive Director Appointment
07Aug17 15:04
RNS
RENE:LON
ReNeuron Group plc
Health
£1.74m
Posting of Annual Report and Notice of AGM
25Jul17 07:00
RNS
RENE:LON
ReNeuron Group plc
Health
£1.74m
Appointment of joint broker
19Jul17 07:00
RNS
RENE:LON
ReNeuron Group plc
Health
£1.74m
Board change
29Jun17 07:00
RNS
RENE:LON
ReNeuron Group plc
Health
£1.74m
Preliminary Results
19Jun17 07:00
RNS
RENE:LON
ReNeuron Group plc
Health
£1.74m
FDA approves cryopreserved hRPC formulation
08Jun17 07:00
RNS
RENE:LON
ReNeuron Group plc
Health
£1.74m
Notification of Preliminary Results
05Jun17 07:00
RNS
RENE:LON
ReNeuron Group plc
Health
£1.74m
Positive FDA feedback on proposed Phase III study
18May17 07:00
RNS
RENE:LON
ReNeuron Group plc
Health
£1.74m
Presents positive exosome data at major conference
11May17 07:00
RNS
RENE:LON
ReNeuron Group plc
Health
£1.74m
Awarded major UK cell therapy manufacturing grant
05May17 07:00
RNS
RENE:LON
ReNeuron Group plc
Health
£1.74m
Presents new exosome data at major conference
21Apr17 07:01
RNS
RENE:LON
ReNeuron Group plc
Health
£1.74m
Update on clinical strategy in stroke disability
21Apr17 07:00
RNS
RENE:LON
ReNeuron Group plc
Health
£1.74m
Update on progress in ophthalmology programmes
07Feb17 12:32
RNS
RENE:LON
ReNeuron Group plc
Health
£1.74m
Director Share Purchase
14Dec16 12:15
RNS
RENE:LON
ReNeuron Group plc
Health
£1.74m
Director Share Purchase
05Dec16 07:00
RNS
RENE:LON
ReNeuron Group plc
Health
£1.74m
Reports Positive Results in Phase II Stroke Trial
05Dec16 07:00
RNS
RENE:LON
ReNeuron Group plc
Health
£1.74m
Interim Results
14Nov16 07:00
RNS
RENE:LON
ReNeuron Group plc
Health
£1.74m
Notification of Interim Results
05Oct16 14:30
RNS
RENE:LON
ReNeuron Group plc
Health
£1.74m
Notification of Major Interest in Shares
06Sep16 12:00
RNS
RENE:LON
ReNeuron Group plc
Health
£1.74m
Result of AGM
06Sep16 07:00
RNS
RENE:LON
ReNeuron Group plc
Health
£1.74m
AGM Trading Update
05Aug16 16:35
RNS
RENE:LON
ReNeuron Group plc
Health
£1.74m
Posting of Annual Report and Notice of AGM
04Aug16 07:00
RNS
RENE:LON
ReNeuron Group plc
Health
£1.74m
Stroke clinical data published in The Lancet
22Jul16 07:00
RNS
RENE:LON
ReNeuron Group plc
Health
£1.74m
Publication of positive pre-clinical retinal data
20Jul16 14:31
RNS
RENE:LON
ReNeuron Group plc
Health
£1.74m
Directors' Interest in Shares and Share Options
07Jul16 07:00
RNS
RENE:LON
ReNeuron Group plc
Health
£1.74m
Preliminary Results
14Jun16 07:00
RNS
RENE:LON
ReNeuron Group plc
Health
£1.74m
Notification of Preliminary Results
13Jun16 07:00
RNS
RENE:LON
ReNeuron Group plc
Health
£1.74m
Patient recruitment completed in stroke trial
09Jun16 07:01
RNS
RENE:LON
ReNeuron Group plc
Health
£1.74m
Pursues brain cancer with exosome platform
08Jun16 07:00
RNS
RENE:LON
ReNeuron Group plc
Health
£1.74m
Retinitis pigmentosa update & Notice of KOL event
31May16 12:45
RNS
RENE:LON
ReNeuron Group plc
Health
£1.74m
Change of Adviser
15Mar16 07:00
RNS
RENE:LON
ReNeuron Group plc
Health
£1.74m
First Patient Treated in RP Clinical Trial
23Feb16 07:00
RNS
RENE:LON
ReNeuron Group plc
Health
£1.74m
ReNeuron Relocates to South Wales
17Feb16 16:57
RNS
RENE:LON
ReNeuron Group plc
Health
£1.74m
Director's Dealings
03Feb16 10:07
RNS
RENE:LON
ReNeuron Group plc
Health
£1.74m
Director Share Purchase
01Feb16 07:00
RNS
RENE:LON
ReNeuron Group plc
Health
£1.74m
Notice of Grant of Key US Patent
12Jan16 07:00
RNS
RENE:LON
ReNeuron Group plc
Health
£1.74m
Pre-clinical data relating to exosome platform
11Jan16 07:00
RNS
RENE:LON
ReNeuron Group plc
Health
£1.74m
Wins UK grant to advance its exosome platform
17Dec15 07:00
RNS
RENE:LON
ReNeuron Group plc
Health
£1.74m
ReNeuron establishes Scientific Advisory Board
07Dec15 07:00
RNS
RENE:LON
ReNeuron Group plc
Health
£1.74m
Interim Results
04Dec15 07:00
RNS
RENE:LON
ReNeuron Group plc
Health
£1.74m
Non-executive Director appointment
12Nov15 14:45
RNS
RENE:LON
ReNeuron Group plc
Health
£1.74m
Notification of Interim Results
06Nov15 15:29
RNS
RENE:LON
ReNeuron Group plc
Health
£1.74m
Total Voting Rights
02Oct15 15:01
RNS
RENE:LON
ReNeuron Group plc
Health
£1.74m
Directors' Interest in Shares and Share Options
14Jun12 07:00
RNS
RENE:LON
ReNeuron Group plc
Health
£1.74m
PISCES Trial Interim Data
«
1
2
3
»
Date / Time
Source
Company
% Chg
16Jul18 07:00
RNS
Aviva plc, ReNeuron Group plc
0.54%
Notification of Major Holdings
13Jul18 11:50
RNS
Aviva plc, ReNeuron Group plc
0.54%
Notification of Major Holdings
12Jul18 07:00
RNS
ReNeuron Group plc
0.00%
Preliminary Results
11Jul18 07:00
RNS
ReNeuron Group plc
0.00%
Signs retinal stem cell exclusivity agreement
04Jul18 14:15
RNS
ReNeuron Group plc
0.00%
Notification of Preliminary Results
17May18 07:00
RNS
ReNeuron Group plc
0.00%
Capital Markets Event
04May18 07:00
RNS
ReNeuron Group plc
0.00%
Exosome data presented at ISCT conference
30Apr18 07:00
RNS
ReNeuron Group plc
0.00%
Capital Markets Event and Webcast
19Apr18 07:00
RNS
ReNeuron Group plc
0.00%
Wins grant for retinal cell therapy development
10Apr18 13:00
RNS
ReNeuron Group plc
0.00%
Appointment of US-based Chief Medical Officer
26Mar18 07:00
RNS
ReNeuron Group plc
0.00%
Product Development Update
13Feb18 10:00
RNS
ReNeuron Group plc
0.00%
Positive pre-clinical data in nerve injury
23Jan18 11:06
RNS
ReNeuron Group plc
0.00%
Approval of Share Capital Reorganisation
11Jan18 07:00
RNS
ReNeuron Group plc
0.00%
Further re Share Capital Reorganisation
05Jan18 07:00
RNS
ReNeuron Group plc
0.00%
Proposed Share Capital Reorganisation
14Dec17 07:00
RNS
ReNeuron Group plc
0.00%
Interim results
14Dec17 07:00
RNS
ReNeuron Group plc
0.00%
Stroke clinical trial regulatory approval in US
08Dec17 07:00
RNS
ReNeuron Group plc
0.00%
ReNeuron opens US office
13Nov17 11:30
RNS
ReNeuron Group plc
0.00%
Notification of Interim Results
08Nov17 07:00
RNS
ReNeuron Group plc
0.00%
Retinal disease clinical trial moves into Phase II
31Oct17 07:00
RNS
ReNeuron Group plc
0.00%
Positive stroke clinical data & regulatory update
27Oct17 07:00
RNS
ReNeuron Group plc
0.00%
Wins further UK grant
11Oct17 13:31
RNS
ReNeuron Group plc
0.00%
PDMR Interest in Shares and Share Options
09Oct17 07:00
RNS
ReNeuron Group plc
0.00%
Presentation of positive pre-clinical data
12Sep17 07:00
RNS
ReNeuron Group plc
0.00%
Directors' Interest in Shares and Share Options
06Sep17 11:15
RNS
ReNeuron Group plc
0.00%
Result of AGM
06Sep17 07:00
RNS
ReNeuron Group plc
0.00%
AGM Trading Update
01Sep17 07:00
RNS
ReNeuron Group plc
0.00%
Non-executive Director Appointment
07Aug17 15:04
RNS
ReNeuron Group plc
0.00%
Posting of Annual Report and Notice of AGM
25Jul17 07:00
RNS
ReNeuron Group plc
0.00%
Appointment of joint broker
19Jul17 07:00
RNS
ReNeuron Group plc
0.00%
Board change
29Jun17 07:00
RNS
ReNeuron Group plc
0.00%
Preliminary Results
19Jun17 07:00
RNS
ReNeuron Group plc
0.00%
FDA approves cryopreserved hRPC formulation
08Jun17 07:00
RNS
ReNeuron Group plc
0.00%
Notification of Preliminary Results
05Jun17 07:00
RNS
ReNeuron Group plc
0.00%
Positive FDA feedback on proposed Phase III study
18May17 07:00
RNS
ReNeuron Group plc
0.00%
Presents positive exosome data at major conference
11May17 07:00
RNS
ReNeuron Group plc
0.00%
Awarded major UK cell therapy manufacturing grant
05May17 07:00
RNS
ReNeuron Group plc
0.00%
Presents new exosome data at major conference
21Apr17 07:01
RNS
ReNeuron Group plc
0.00%
Update on clinical strategy in stroke disability
21Apr17 07:00
RNS
ReNeuron Group plc
0.00%
Update on progress in ophthalmology programmes
07Feb17 12:32
RNS
ReNeuron Group plc
0.00%
Director Share Purchase
14Dec16 12:15
RNS
ReNeuron Group plc
0.00%
Director Share Purchase
05Dec16 07:00
RNS
ReNeuron Group plc
0.00%
Reports Positive Results in Phase II Stroke Trial
05Dec16 07:00
RNS
ReNeuron Group plc
0.00%
Interim Results
14Nov16 07:00
RNS
ReNeuron Group plc
0.00%
Notification of Interim Results
05Oct16 14:30
RNS
ReNeuron Group plc
0.00%
Notification of Major Interest in Shares
06Sep16 12:00
RNS
ReNeuron Group plc
0.00%
Result of AGM
06Sep16 07:00
RNS
ReNeuron Group plc
0.00%
AGM Trading Update
05Aug16 16:35
RNS
ReNeuron Group plc
0.00%
Posting of Annual Report and Notice of AGM
04Aug16 07:00
RNS
ReNeuron Group plc
0.00%
Stroke clinical data published in The Lancet
22Jul16 07:00
RNS
ReNeuron Group plc
0.00%
Publication of positive pre-clinical retinal data
20Jul16 14:31
RNS
ReNeuron Group plc
0.00%
Directors' Interest in Shares and Share Options
07Jul16 07:00
RNS
ReNeuron Group plc
0.00%
Preliminary Results
14Jun16 07:00
RNS
ReNeuron Group plc
0.00%
Notification of Preliminary Results
13Jun16 07:00
RNS
ReNeuron Group plc
0.00%
Patient recruitment completed in stroke trial
09Jun16 07:01
RNS
ReNeuron Group plc
0.00%
Pursues brain cancer with exosome platform
08Jun16 07:00
RNS
ReNeuron Group plc
0.00%
Retinitis pigmentosa update & Notice of KOL event
31May16 12:45
RNS
ReNeuron Group plc
0.00%
Change of Adviser
15Mar16 07:00
RNS
ReNeuron Group plc
0.00%
First Patient Treated in RP Clinical Trial
23Feb16 07:00
RNS
ReNeuron Group plc
0.00%
ReNeuron Relocates to South Wales
17Feb16 16:57
RNS
ReNeuron Group plc
0.00%
Director's Dealings
03Feb16 10:07
RNS
ReNeuron Group plc
0.00%
Director Share Purchase
01Feb16 07:00
RNS
ReNeuron Group plc
0.00%
Notice of Grant of Key US Patent
12Jan16 07:00
RNS
ReNeuron Group plc
0.00%
Pre-clinical data relating to exosome platform
11Jan16 07:00
RNS
ReNeuron Group plc
0.00%
Wins UK grant to advance its exosome platform
17Dec15 07:00
RNS
ReNeuron Group plc
0.00%
ReNeuron establishes Scientific Advisory Board
07Dec15 07:00
RNS
ReNeuron Group plc
0.00%
Interim Results
04Dec15 07:00
RNS
ReNeuron Group plc
0.00%
Non-executive Director appointment
12Nov15 14:45
RNS
ReNeuron Group plc
0.00%
Notification of Interim Results
06Nov15 15:29
RNS
ReNeuron Group plc
0.00%
Total Voting Rights
02Oct15 15:01
RNS
ReNeuron Group plc
0.00%
Directors' Interest in Shares and Share Options
14Jun12 07:00
RNS
ReNeuron Group plc
0.00%
PISCES Trial Interim Data
«
1
2
3
»
Date / Time
Company
% Chg
16Jul18 07:00
AV. LSE,RENE LSE
0.54%
Notification of Major Holdings
13Jul18 11:50
AV. LSE,RENE LSE
0.54%
Notification of Major Holdings
12Jul18 07:00
ReNeuron Group plc
0.00%
Preliminary Results
11Jul18 07:00
ReNeuron Group plc
0.00%
Signs retinal stem cell exclusivity agreement
04Jul18 14:15
ReNeuron Group plc
0.00%
Notification of Preliminary Results
17May18 07:00
ReNeuron Group plc
0.00%
Capital Markets Event
04May18 07:00
ReNeuron Group plc
0.00%
Exosome data presented at ISCT conference
30Apr18 07:00
ReNeuron Group plc
0.00%
Capital Markets Event and Webcast
19Apr18 07:00
ReNeuron Group plc
0.00%
Wins grant for retinal cell therapy development
10Apr18 13:00
ReNeuron Group plc
0.00%
Appointment of US-based Chief Medical Officer
26Mar18 07:00
ReNeuron Group plc
0.00%
Product Development Update
13Feb18 10:00
ReNeuron Group plc
0.00%
Positive pre-clinical data in nerve injury
23Jan18 11:06
ReNeuron Group plc
0.00%
Approval of Share Capital Reorganisation
11Jan18 07:00
ReNeuron Group plc
0.00%
Further re Share Capital Reorganisation
05Jan18 07:00
ReNeuron Group plc
0.00%
Proposed Share Capital Reorganisation
14Dec17 07:00
ReNeuron Group plc
0.00%
Interim results
14Dec17 07:00
ReNeuron Group plc
0.00%
Stroke clinical trial regulatory approval in US
08Dec17 07:00
ReNeuron Group plc
0.00%
ReNeuron opens US office
13Nov17 11:30
ReNeuron Group plc
0.00%
Notification of Interim Results
08Nov17 07:00
ReNeuron Group plc
0.00%
Retinal disease clinical trial moves into Phase II
31Oct17 07:00
ReNeuron Group plc
0.00%
Positive stroke clinical data & regulatory update
27Oct17 07:00
ReNeuron Group plc
0.00%
Wins further UK grant
11Oct17 13:31
ReNeuron Group plc
0.00%
PDMR Interest in Shares and Share Options
09Oct17 07:00
ReNeuron Group plc
0.00%
Presentation of positive pre-clinical data
12Sep17 07:00
ReNeuron Group plc
0.00%
Directors' Interest in Shares and Share Options
06Sep17 11:15
ReNeuron Group plc
0.00%
Result of AGM
06Sep17 07:00
ReNeuron Group plc
0.00%
AGM Trading Update
01Sep17 07:00
ReNeuron Group plc
0.00%
Non-executive Director Appointment
07Aug17 15:04
ReNeuron Group plc
0.00%
Posting of Annual Report and Notice of AGM
25Jul17 07:00
ReNeuron Group plc
0.00%
Appointment of joint broker
19Jul17 07:00
ReNeuron Group plc
0.00%
Board change
29Jun17 07:00
ReNeuron Group plc
0.00%
Preliminary Results
19Jun17 07:00
ReNeuron Group plc
0.00%
FDA approves cryopreserved hRPC formulation
08Jun17 07:00
ReNeuron Group plc
0.00%
Notification of Preliminary Results
05Jun17 07:00
ReNeuron Group plc
0.00%
Positive FDA feedback on proposed Phase III study
18May17 07:00
ReNeuron Group plc
0.00%
Presents positive exosome data at major conference
11May17 07:00
ReNeuron Group plc
0.00%
Awarded major UK cell therapy manufacturing grant
05May17 07:00
ReNeuron Group plc
0.00%
Presents new exosome data at major conference
21Apr17 07:01
ReNeuron Group plc
0.00%
Update on clinical strategy in stroke disability
21Apr17 07:00
ReNeuron Group plc
0.00%
Update on progress in ophthalmology programmes
07Feb17 12:32
ReNeuron Group plc
0.00%
Director Share Purchase
14Dec16 12:15
ReNeuron Group plc
0.00%
Director Share Purchase
05Dec16 07:00
ReNeuron Group plc
0.00%
Reports Positive Results in Phase II Stroke Trial
05Dec16 07:00
ReNeuron Group plc
0.00%
Interim Results
14Nov16 07:00
ReNeuron Group plc
0.00%
Notification of Interim Results
05Oct16 14:30
ReNeuron Group plc
0.00%
Notification of Major Interest in Shares
06Sep16 12:00
ReNeuron Group plc
0.00%
Result of AGM
06Sep16 07:00
ReNeuron Group plc
0.00%
AGM Trading Update
05Aug16 16:35
ReNeuron Group plc
0.00%
Posting of Annual Report and Notice of AGM
04Aug16 07:00
ReNeuron Group plc
0.00%
Stroke clinical data published in The Lancet
22Jul16 07:00
ReNeuron Group plc
0.00%
Publication of positive pre-clinical retinal data
20Jul16 14:31
ReNeuron Group plc
0.00%
Directors' Interest in Shares and Share Options
07Jul16 07:00
ReNeuron Group plc
0.00%
Preliminary Results
14Jun16 07:00
ReNeuron Group plc
0.00%
Notification of Preliminary Results
13Jun16 07:00
ReNeuron Group plc
0.00%
Patient recruitment completed in stroke trial
09Jun16 07:01
ReNeuron Group plc
0.00%
Pursues brain cancer with exosome platform
08Jun16 07:00
ReNeuron Group plc
0.00%
Retinitis pigmentosa update & Notice of KOL event
31May16 12:45
ReNeuron Group plc
0.00%
Change of Adviser
15Mar16 07:00
ReNeuron Group plc
0.00%
First Patient Treated in RP Clinical Trial
23Feb16 07:00
ReNeuron Group plc
0.00%
ReNeuron Relocates to South Wales
17Feb16 16:57
ReNeuron Group plc
0.00%
Director's Dealings
03Feb16 10:07
ReNeuron Group plc
0.00%
Director Share Purchase
01Feb16 07:00
ReNeuron Group plc
0.00%
Notice of Grant of Key US Patent
12Jan16 07:00
ReNeuron Group plc
0.00%
Pre-clinical data relating to exosome platform
11Jan16 07:00
ReNeuron Group plc
0.00%
Wins UK grant to advance its exosome platform
17Dec15 07:00
ReNeuron Group plc
0.00%
ReNeuron establishes Scientific Advisory Board
07Dec15 07:00
ReNeuron Group plc
0.00%
Interim Results
04Dec15 07:00
ReNeuron Group plc
0.00%
Non-executive Director appointment
12Nov15 14:45
ReNeuron Group plc
0.00%
Notification of Interim Results
06Nov15 15:29
ReNeuron Group plc
0.00%
Total Voting Rights
02Oct15 15:01
ReNeuron Group plc
0.00%
Directors' Interest in Shares and Share Options
14Jun12 07:00
ReNeuron Group plc
0.00%
PISCES Trial Interim Data
«
1
2
3
»
Strapline
Strapline
Question 1
Answer 1
Question 2
Answer 2
Question 3
Answer 3
Question 4
Answer 4
Question 5
Answer 5
Question 6
Answer 6
Question 7
Answer 7
Question 8
Answer 8
Top
Home
Features
Pricing
Event Hub
Reg.News
Short Interest Tracker
Explore Content
Regions
UK
Rest of EMEA
N America
APAC
LatAm
Exchanges
Aquis Apex
Australian Securities Exchange
Canadian Securities Exchange
Euronext Paris
London Stock Exchange (domestic)
SIX Swiss Exchange
Sectors
Automobile Industry
Banks
Building & Construction
Chemicals
Discretionary Personal Goods
Discretionary Retail
Energy
ETFs
Financial Services
Food & Drink
Food Production
Health
Household Goods & DIY
Industrial Equipment, Goods & Services
Insurance & Reinsurance
Investment Trusts
Leisure, Tourism & Travel
Media
Open-ended Funds
Other
Real Estate
Resources
Staple Retail
Technology
Telecoms
Utilities
Small / Large Cap
UK100
UK250
UK Smallcap
UK Other Main Markets
Other
Private/EIS
EIS Single Company
EIS/SEIS Funds
IHT Products
SEIS Single Company
VCT Funds
Providers
Free/Commissioned
ACF Equity Research
Actio Advisors
Align Research
Atrium Research
BlytheRay
BNP Paribas Exane - Sponsored Research
Brand Communications
BRR Media
Calvine Partners
Capital Access Group
Capital Markets Brokers
Cavendish
Checkpoint Partners
Clear Capital Markets
Couloir Capital
Degroof Petercam
DirectorsTalk
Doceo
Edison
Equity Development
eResearch
Fidante Partners
Five Minute Pitch TV
focusIR
Fundamental Research Corp
Galliano’s Latin Notes
goetzpartners securities Limited
H2 Radnor
Hardman & Co
Holland Advisors
Hypothesis Research
Inbound Capital
Independent Investment Research
InterAxS Global
Kepler | Trust Intelligence
Liberum
London Stock Exchange
Magnitogorsk Iron and steel works
Mello Events
Mining Network
NuWays
Paul Scott
Peel Hunt
piworld.co.uk
Proactive
Progressive Equity Research
Quantum Research Group
QuotedData
RaaS - Research as a Service
Research Tree
Resolve Research
SEAL Advisors Ltd
ShareSoc
Shore Capital
Small Cap Consumer Research LLC
StockBox
Tennyson Securities
The AIC
The Life Sciences Division
Trinity Delta
Turner Pope Investments
UK Investor Group
Vox Markets
VSA Capital
WHIreland
Winterflood Securities
Yellowstone Advisory
Zeus Capital
High Net Worth Offering
Fox-Davies Capital
ACF Equity Research
Align Research
Allenby Capital
AlphaValue
Alternative Resource Capital
Arctic Securities
Arden Partners
Auctus Advisors
Baptista Research
BNP Paribas Exane - Sponsored Research
Canaccord Genuity
Cavendish
Couloir Capital
Dowgate Capital
First Berlin
First Sentinel
GSBR Research
Hannam & Partners
Hybridan
Kemeny Capital
Liberum
Longspur Clean Energy
Louis Capital
Magnitogorsk Iron and steel works
Medley Global Advisors
Northland Capital Partners
QuotedData Professional
Shard Capital
ShareSoc
Shore Capital
Singer Capital Markets
SP Angel
Stanford Capital Partners
Stifel FirstEnergy
Stockdale Securities
Tamesis Partners
Tennyson Securities
The Life Sciences Division
Turner Pope Investments
VSA Capital
WHIreland
Whitman Howard
Yellowstone Advisory
Zeus Capital
Institutional Offering
Fox-Davies Capital
ACF Equity Research
Align Research
Allenby Capital
Alternative Resource Capital
Arctic Securities
Arden Partners
Auctus Advisors
BNP Paribas Exane
BRR Media
Calvine Partners
Canaccord Genuity
Capital Access Group
Cavendish
Checkpoint Partners
Clear Capital Markets
Couloir Capital
Degroof Petercam
DirectorsTalk
Doceo
Dowgate Capital
Edison
Equity Development
eResearch
Fidante Partners
First Berlin
First Sentinel
Five Minute Pitch TV
Fundamental Research Corp
Galliano’s Latin Notes
Goodbody
H2 Radnor
Hannam & Partners
Hardman & Co
Holland Advisors
Hybridan
Inbound Capital
Independent Investment Research
InterAxS Global
Investec Bank
Kemeny Capital
Kepler | Absolute Hedge
Kepler | Trust Intelligence
Liberum
London Stock Exchange
Longspur Clean Energy
Magnitogorsk Iron and steel works
Mello Events
Mining Network
Northland Capital Partners
Numis
NuWays
Panmure Gordon
Peel Hunt
piworld.co.uk
Proactive
Quantum Research Group
QuotedData
RaaS - Research as a Service
Research Tree
Shard Capital
ShareSoc
Shore Capital
Singer Capital Markets
Small Cap Consumer Research LLC
SP Angel
Stanford Capital Partners
Stifel
StockBox
Tamesis Partners
Tennyson Securities
The AIC
The Life Sciences Division
Trinity Delta
UK Investor Group
Velocity Trade
Vox Markets
VSA Capital
WHIreland
Winterflood Securities
Yellowstone Advisory
Zeus Capital
Contact
Sign Up
Sign In
Share: